alpn-20231106

0001626199-23-000106.txt : 20231106 0001626199-23-000106.hdr.sgml : 20231106 20231106060235 ACCESSION NUMBER: 0001626199-23-000106 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231106 ITEM INFORMATION: Results of Operations and Financial Condition FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ALPINE IMMUNE SCIENCES, INC. CENTRAL INDEX KEY: 0001626199 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208969493 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37449 FILM NUMBER: 231377971 BUSINESS ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 BUSINESS PHONE: 206-788-4545 MAIL ADDRESS: STREET 1: 188 EAST BLAINE ST., SUITE 200 CITY: SEATTLE STATE: WA ZIP: 98102 FORMER COMPANY: FORMER CONFORMED NAME: Nivalis Therapeutics, Inc. DATE OF NAME CHANGE: 20150211 FORMER COMPANY: FORMER CONFORMED NAME: N30 Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20141121 8-K 1 alpn-20231106.htm 8-K alpn-20231106

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2023

ALPINE IMMUNE SCIENCES, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-37449

20-8969493

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

188 East Blaine Street, Suite 200

Seattle, Washington 98102

(Address of principal executive offices, including zip code)

(206) 788-4545

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of each exchange on which registered

Common Stock, par value $0.001 per share

ALPN

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2023, Alpine Immune Sciences, Inc. (the “Company”), announced preliminary unaudited financial highlights for the third quarter of 2023. Based upon preliminary estimates and information available to the Company as of the date of this Form 8-K:

•As of September 30, 2023, the Company had approximately $227.2 million in cash, cash equivalents, restricted cash and investments.

•For the three and nine months ended September 30, 2023, the Company expects operating expenses to be approximately $24.6 million and $73.8 million, respectively, compared to operating expenses of $22.2 million and $65.1 million during the three and nine months ended September 30, 2022, respectively.

The foregoing estimates as of and for the three and nine months ended September 30, 2023 are preliminary. The Company is in the process of finalizing the actual results of operations for the three and nine months ended September 30, 2023 and therefore final results are not yet available. These preliminary estimates are based solely upon information available to the Company as of the date of this Current Report on Form 8-K and our actual results may differ from these estimates due to the completion of our quarter-end closing procedures, final adjustments, review by our independent registered public accounting firm and developments that may arise between now and the time our financial results for the three and nine months ended September 30, 2023 are finalized. Additional information and disclosure would be required for a more complete understanding of the Company’s financial position and results of operations as of and for the three and nine months ended September 30, 2023. Investors should refer to the Company’s actual results included in its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2023 once they become available.

The Company’s independent registered public accounting firm has not audited, reviewed or performed any procedures with respect to these preliminary estimates and, accordingly, does not express an opinion or any other form of assurance about them.

The information furnished under this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

This Current Report on Form 8-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding our preliminary financial results as of and for the three and nine months ended September 30, 2023. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include the risk that our actual financial results for the three and nine months ended September 30, 2023 differ from the estimates presented in this Current Report on Form 8-K; as well as the other risks set forth in our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. The Company disclaims any obligation to update these forward-looking statements.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 6, 2023

ALPINE IMMUNE SCIENCES, INC.

By:

/s/ Paul Rickey

Name:

Paul Rickey

Title:

Senior Vice President and Chief Financial Officer

EX-101.SCH 2 alpn-20231106.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 alpn-20231106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 4 alpn-20231106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Nov. 06, 2023
Cover [Abstract]
Entity Central Index Key	0001626199
Amendment Flag	false
Document Type	8-K
Document Period End Date	Nov. 06, 2023
Entity Registrant Name	ALPINE IMMUNE SCIENCES, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-37449
Entity Tax Identification Number	20-8969493
Entity Address, Address Line One	188 East Blaine Street
Entity Address, Address Line Two	Suite 200
Entity Address, City or Town	Seattle
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98102
City Area Code	206
Local Phone Number	788-4545
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	ALPN
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

XML 6 alpn-20231106_htm.xml IDEA: XBRL DOCUMENT 0001626199 2023-11-06 2023-11-06 0001626199 false 8-K 2023-11-06 ALPINE IMMUNE SCIENCES, INC. DE 001-37449 20-8969493 188 East Blaine Street Suite 200 Seattle WA 98102 206 788-4545 false false false false Common Stock, par value $0.001 per share ALPN NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " !1,&9799!YDAD! #/ P $P M @ &Z$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" $ %% ! end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://www.alpineimmunesciences.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports alpn-20231106.htm alpn-20231106.xsd alpn-20231106_lab.xml alpn-20231106_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "alpn-20231106.htm": { "nsprefix": "alpn", "nsuri": "http://www.alpineimmunesciences.com/20231106", "dts": { "inline": { "local": [ "alpn-20231106.htm" ] }, "schema": { "local": [ "alpn-20231106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "alpn-20231106_lab.xml" ] }, "presentationLink": { "local": [ "alpn-20231106_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.alpineimmunesciences.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "alpn-20231106.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "alpn-20231106.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.alpineimmunesciences.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0001626199-23-000106-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001626199-23-000106-xbrl.zip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end